(1-methylsulfonyl-4-piperidinyl)-(4-morpholinyl)methanone is a chemical compound with the molecular formula C11H20N2O4S. It is more commonly known as **(1-methylsulfonyl-4-piperidinyl)morpholine amide**, or simply **MSP**.
**Importance in Research:**
MSP is a potent and selective **agonist** of the **µ-opioid receptor**. This means it binds to and activates the µ-opioid receptor, which is a major target for pain relief, addiction, and other therapeutic applications.
Here's why MSP is important for research:
* **Understanding Opioid Pharmacology:** MSP has been used extensively in research to study the structure-activity relationships of µ-opioid receptor agonists and to develop new analgesics with improved efficacy and reduced side effects.
* **Drug Discovery:** MSP serves as a valuable lead compound for the development of novel opioid analgesics. Researchers can modify its structure to enhance its pharmacological properties, such as potency, selectivity, and bioavailability.
* **Addiction Research:** MSP can be used to investigate the mechanisms of opioid dependence and addiction. Its ability to activate the µ-opioid receptor allows researchers to study the cellular and molecular events involved in addiction.
* **Pain Management:** MSP has demonstrated analgesic activity in animal models of pain. Its potency and selectivity for the µ-opioid receptor make it a potential candidate for treating chronic pain conditions.
**However, it's important to note that MSP is a research tool and not currently approved for therapeutic use. Further studies are needed to evaluate its safety and efficacy in humans.**
**Other relevant information:**
* MSP is a white solid with a melting point of 150-152°C.
* It is soluble in methanol, ethanol, and chloroform.
* MSP is a chiral molecule, with two enantiomers (R-MSP and S-MSP) that exhibit different pharmacological profiles.
Overall, MSP is a valuable tool for research in the field of opioid pharmacology, drug discovery, and pain management. It provides insights into the mechanisms of opioid action and serves as a lead compound for the development of novel analgesics with improved therapeutic potential.
ID Source | ID |
---|---|
PubMed CID | 647201 |
CHEMBL ID | 1509745 |
CHEBI ID | 116173 |
Synonym |
---|
AKOS000439814 |
MLS000034203 |
smr000013611 |
(1-methanesulfonyl-piperidin-4-yl)-morpholin-4-yl-methanone |
CHEBI:116173 |
(1-methylsulfonylpiperidin-4-yl)-morpholin-4-ylmethanone |
[1-(methylsulfonyl)piperidin-4-yl](morpholin-4-yl)methanone |
STK891652 |
HMS2340N23 |
CHEMBL1509745 |
Q27198905 |
(1-methylsulfonyl-4-piperidinyl)-(4-morpholinyl)methanone |
Class | Description |
---|---|
piperidinecarboxamide | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
ATAD5 protein, partial | Homo sapiens (human) | Potency | 16.3601 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 1.0000 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
geminin | Homo sapiens (human) | Potency | 35.4813 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 0.0224 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |